Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

Solbec Announces Grant Of Australian Patent

SOLBEC ANNOUNCES GRANT OF AUSTRALIAN PATENT

Summary:
· Solbec advises the granting of Australian patent, number 779512, entitled “Medicinal compositions and their method of preparation”.


Perth, Australia. 14 June 2005. Solbec Pharmaceuticals (ASX: SBP) advises that the Australian patent, number 779512, entitled “Medicinal compositions and their method of preparation” has been granted. This provides additional protection to the Company’s lead compound Coramsine™. The term of the patent runs until April 2020.

The “Medicinal compositions” patent covers aspects of the manufacturing, purification process and formulation of the active pharmaceutical ingredients of Coramsine™. It is the second Coramsine™ related patent application to be granted. International cases of the application are ongoing.

Coramsine™ is now covered by seven families of patents / patent applications that are expected to provide protection until 2023. They extend to clinical application, extraction and purification, the cell receptor involved in Coramsine™ selectivity, Coramsine’s™ effect on Interleukin-6 production, and Coramsine™ combination therapy.

Background Information

Solbec Pharmaceuticals Ltd identifies naturally-occurring compounds with potential in the development of better therapies for debilitating conditions and life-threatening diseases. The company is currently progressing its key project, Coramsine™, through Phase I/IIA clinical trials for the treatment of advanced solid tumours, and as a topical treatment for psoriasis. Solbec's two proprietary ingredients in Coramsine™ were isolated from the fruit of a plant known as the Devil’s Apple (Solanum linnaeanum). They show activity against some cancers and cause potentially therapeutic changes to the immune system. In addition to human health, Coramsine™ has potential application in the areas of animal health and diagnostics. Solbec’s business strategy is to partner or out-license Coramsine™ for the final stages of pre-commercial development and marketing.

www.solbec.com.au

© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Voluntary Administration: Renaissance Brewing Up For Sale

Renaissance Brewing, the first local company to raise capital through equity crowdfunding, is up for sale after cash flow woes and product management issues led to the appointment of voluntary administrators. More>>

Elsewhere:

Approval: Northern Corridor Decision Released

The approval gives the green light to construction of the last link of Auckland’s Western Ring Route, providing an alternative route from South Auckland to the North Shore. More>>

ALSO:

Media Mega Merger: Full Steam Ahead For Appeal

New Zealand's two largest news publishers have confirmed they are committed to pursuing their appeal against the Commerce Commission's rejection of the proposal to merge their operations. More>>

Crown Accounts: $4.1 Billion Surplus

The New Zealand Government has achieved its third fiscal surplus in a row with the Crown accounts for the year ended 30 June 2017 showing an OBEGAL surplus of $4.1 billion, $2.2 billion stronger than last year, Finance Minister Steven Joyce says. More>>

ALSO:

Mycoplasma Bovis: One New Property Tests Positive

The newly identified property... was already under a Restricted Place notice under the Biosecurity Act. More>>

Accounting Scandal: Suspension Of Fuji Xerox From All-Of-Government Contract

General Manager of New Zealand Government Procurement John Ivil says, “FXNZ has been formally suspended from the Print Technology and Associated Services (PTAS) contract and terminated from the Office Supplies contract.” More>>